查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1784039

精准基因组检测的全球市场

Precision Genomic Testing
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 222 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计2030年全球精准基因组检测市场规模将达423亿美元

全球精准基因组检测市场规模预计在2024年达到167亿美元，预计在分析期内（2024-2030年）的复合年增长率为16.7%，到2030年将达到423亿美元。基因组检测耗材是本报告分析的细分市场之一，预计其复合年增长率为18.2%，至分析期末达246亿美元。基因组检测设备细分市场在分析期间内的复合年增长率预计为15.3%。

美国市场规模估计为 44 亿美元，中国市场预计复合年增长率为 15.7%

美国精准基因组检测市场规模预计在2024年达到44亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到65亿美元，在2024-2030年的分析期间内，复合年增长率为15.7%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为15.6%和14.3%。在欧洲，预计德国市场的复合年增长率约为12.1%。

全球精准基因组检测市场—主要趋势与驱动因素摘要

精准基因组检测将如何改变医疗保健？

精准基因组检测正在彻底改变现代医学，它能够实现个人化诊断、标靶治疗和早期疾病检测。透过分析个体的基因组成，医疗保健提供者可以根据基因变异制定个人化治疗方案，从而显着改善患者的预后。这种方法在肿瘤学、罕见疾病、药物基因组学和生殖医学领域尤其有效，因为基因洞察在这些领域的治疗决策中发挥关键作用。

次世代定序仪(NGS)、基于 CRISPR 的基因编辑以及人工智慧主导的生物资讯学的扩展，正在加速精准基因组检测在各个医疗领域的应用。全基因组定序 (WGS)、全外EXOME定序 (WES) 和液态切片技术的进步正在提高诊断准确性，并使基因组检测更加便利且更具成本效益。随着基因研究的不断发展，包括蛋白质体学和代谢体学在内的多组体学的整合，正在进一步改善精准医疗的应用。

哪些市场趋势正在推动精准基因组检测的成长？

影响精准基因组检测市场最重要的趋势之一是个人化医疗需求的持续成长。人们日益认识到基因差异会影响药物反应，这推动了药物基因体学的扩展，该技术可根据个体的基因图谱确定最有效的药物。这在肿瘤学、循环系统和神经内科等领域尤其重要，因为遗传因素会显着影响治疗结果。

另一个重要趋势是直接面向消费者 (DTC) 的基因检测日益普及。提供用于家谱、疾病风险评估和生活方式建议的家用基因组检测套组的公司日益普及，并正在推动市场扩张。然而，监管监督和资料隐私方面的伦理问题仍然是该领域面临的重大挑战。

人工智慧和巨量资料分析的进步也正在改变基因组检测的模式。机器学习演算法正被用于解读海量基因组数据，从而提高疾病风险预测和生物标记发现的准确性。此外，云端基础的基因组资料库正在促进大规模基因研究，加速复杂疾病和潜在治疗标靶的研究。

哪些地区在精准基因组检测上处于领先地位？

北美在精准基因组检测市场占据主导地位，这得益于雄厚的科研经费、个人化医疗的普及率以及先进的医疗基础设施。美国凭藉其在基因组学研究方面的大量投入、「我们所有人」研究计划等政府倡议以及生物技术公司与学术机构之间的合作，占据了领先地位。

欧洲也是一个重要的参与者，得益于监管支持、官民合作关係以及人们对基因检测临床益处日益增长的认识。德国、英国和法国等国家正在推动精准医疗，重点是将基因组数据整合到医疗保健系统中，以改善病患照护。

受生物技术投资增加、医疗保健可近性扩大以及政府推动精准医疗倡议的推动，基因组检测在亚太地区发展迅速。中国、日本和韩国均设有专门收集和分析基因组数据的国家项目，引领该地区的基因组研究工作。同时，拉丁美洲和中东等新兴市场也逐步采用精准基因组检测，但高昂的成本和有限的基础设施仍是其广泛应用的障碍。

精准基因组检测市场的成长受多种因素驱动

市场成长的主要驱动力之一是癌症、神经退化性疾病、心血管疾病等遗传和复杂疾病的盛行率不断上升。随着早期发现和风险评估在医疗保健中变得越来越重要，基因组检测在指南预防措施和精准治疗方面发挥着至关重要的作用。

定序平台的技术进步，例如经济高效的超快速定序技术的开发，正在使基因组检测更加便利。可携式定序设备和自动化工作流程的出现，进一步扩大了精准医疗的覆盖范围，使其从专业实验室延伸至临床环境和照护现场诊断。

监管支持和资助措施也在加速市场应用。世界各国政府正在投资国家基因组资料库和精准医疗项目，促进医疗保健提供者、研究机构和生物技术公司之间的合作。此外，基因检测的报销政策也不断发展，提高了患者获得基因组诊断服务的可负担性和可近性。

随着基因组学领域的不断发展，人工智慧、云端处理和分子生物学的融合将进一步提升精准基因组检测的能力。该市场预计将重新定义疾病管理、药物开发和预防性医疗保健，并有望实现显着成长，塑造全球个人化医疗的未来。

部分

类型（基因组检测耗材、基因组检测设备、基因组检测服务）、技术类型（二代定序技术、聚合酵素链锁反应技术、微阵列技术、桑格定序技术、CRISPR/CAS系统技术、其他技术类型）、应用领域（肿瘤学应用、心血管疾病应用、神经科疾病应用、生殖医学应用实验室、罕见疾病应用、其他学术用途

受访公司范例

  • 23andMe
  • Ambry Genetics
  • BGI Genomics
  • Centogene NV
  • Color Health, Inc.
  • Exact Sciences Corporation
  • Foundation Medicine
  • Fulgent Genetics
  • GeneDx
  • Genomic Health（a subsidiary of Exact Sciences）
  • Guardant Health
  • Illumina, Inc.
  • Invitae Corporation
  • Luminex Corporation
  • Myriad Genetics
  • Natera, Inc.
  • NeoGenomics Laboratories
  • Oxford Nanopore Technologies
  • Qiagen
  • Thermo Fisher Scientific

人工智慧集成

全球产业分析师利用可操作的专家内容和人工智慧工具改变市场和竞争情报。

Global Industry Analysts 没有遵循查询 LLM 或特定产业SLM 的典型规范，而是建立了一个来自世界各地专家的精选内容库，其中包括视频录像、博客、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地和进出口（成品和原始设备製造商）情况预测其竞争地位的变化。这种复杂而多面的市场动态预计将以多种方式影响竞争对手，包括销货成本(COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲国家
  • 亚太地区
  • 其他地区

第四章 比赛

简介目录
Product Code: MCP32666

Global Precision Genomic Testing Market to Reach US$42.3 Billion by 2030

The global market for Precision Genomic Testing estimated at US$16.7 Billion in the year 2024, is expected to reach US$42.3 Billion by 2030, growing at a CAGR of 16.7% over the analysis period 2024-2030. Genomic Testing Consumables, one of the segments analyzed in the report, is expected to record a 18.2% CAGR and reach US$24.6 Billion by the end of the analysis period. Growth in the Genomic Testing Equipment segment is estimated at 15.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.4 Billion While China is Forecast to Grow at 15.7% CAGR

The Precision Genomic Testing market in the U.S. is estimated at US$4.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.5 Billion by the year 2030 trailing a CAGR of 15.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.6% and 14.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.1% CAGR.

Global Precision Genomic Testing Market - Key Trends & Drivers Summarized

How Is Precision Genomic Testing Transforming Healthcare?

Precision genomic testing is revolutionizing modern medicine by enabling personalized diagnostics, targeted therapies, and early disease detection. By analyzing an individual's genetic makeup, healthcare providers can tailor treatments based on genetic variations, significantly improving patient outcomes. This approach is particularly impactful in oncology, rare diseases, pharmacogenomics, and reproductive health, where genetic insights play a crucial role in treatment decisions.

The expansion of next-generation sequencing (NGS), CRISPR-based gene editing, and AI-driven bioinformatics has accelerated the adoption of precision genomic testing across various medical fields. Advances in whole genome sequencing (WGS), whole exome sequencing (WES), and liquid biopsy techniques are enhancing diagnostic accuracy, making genomic testing more accessible and cost-effective. As genetic research continues to evolve, the integration of multi-omics approaches-including proteomics and metabolomics-is further refining precision medicine applications.

What Market Trends Are Driving Growth in Precision Genomic Testing?

One of the most significant trends shaping the precision genomic testing market is the increasing demand for personalized medicine. The growing recognition that genetic differences influence drug response has fueled the expansion of pharmacogenomics, which helps determine the most effective medications for individuals based on their genetic profiles. This is particularly important in fields such as oncology, cardiology, and neurology, where genetic factors significantly impact treatment efficacy.

Another key trend is the rising adoption of direct-to-consumer (DTC) genetic testing. Companies offering at-home genomic testing kits for ancestry, disease risk assessment, and lifestyle recommendations have gained popularity, driving market expansion. However, regulatory scrutiny and ethical concerns regarding data privacy remain key challenges in this sector.

Advancements in AI and big data analytics are also transforming the genomic testing landscape. Machine learning algorithms are being used to interpret vast amounts of genomic data, improving the accuracy of disease risk prediction and biomarker discovery. Additionally, cloud-based genomic databases are facilitating large-scale genetic studies, accelerating research into complex diseases and potential therapeutic targets.

Which Regions Are Leading in Precision Genomic Testing Adoption?

North America dominates the precision genomic testing market, driven by strong research funding, high adoption of personalized medicine, and advanced healthcare infrastructure. The United States leads the way with significant investments in genomics research, government initiatives such as the All of Us Research Program, and collaborations between biotech firms and academic institutions.

Europe is also a key player, benefiting from regulatory support, public-private partnerships, and growing awareness of genetic testing’s clinical benefits. Countries like Germany, the UK, and France are advancing precision medicine initiatives, with an emphasis on integrating genomic data into healthcare systems to improve patient care.

Asia-Pacific is experiencing rapid growth in genomic testing, fueled by increasing investments in biotechnology, expanding healthcare access, and government initiatives promoting precision medicine. China, Japan, and South Korea are leading the region’s genomic research efforts, with national programs dedicated to genomic data collection and analysis. Meanwhile, emerging markets in Latin America and the Middle East are gradually adopting precision genomic testing, although challenges such as high costs and limited infrastructure remain barriers to widespread implementation.

The Growth in the Precision Genomic Testing Market Is Driven by Several Factors

One of the primary drivers of market growth is the increasing prevalence of genetic disorders and complex diseases such as cancer, neurodegenerative conditions, and cardiovascular diseases. As early detection and risk assessment become more critical in healthcare, genomic testing is playing an essential role in guiding preventative measures and precision therapies.

Technological advancements in sequencing platforms, including the development of cost-efficient and ultra-fast sequencing techniques, are making genomic testing more accessible. The emergence of portable sequencing devices and automated workflows is further expanding the reach of precision medicine beyond specialized laboratories to clinical settings and point-of-care diagnostics.

Regulatory support and funding initiatives are also accelerating market adoption. Governments worldwide are investing in national genomic databases and precision medicine programs, promoting collaboration between healthcare providers, research institutions, and biotech companies. Additionally, reimbursement policies for genetic testing are evolving, improving affordability and patient access to genomic-based diagnostics.

As the field of genomics continues to advance, the convergence of AI, cloud computing, and molecular biology will further enhance the capabilities of precision genomic testing. With its potential to redefine disease management, drug development, and preventative healthcare, the market is poised for substantial growth, shaping the future of personalized medicine worldwide.

SCOPE OF STUDY:

The report analyzes the Precision Genomic Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Genomic Testing Consumables, Genomic Testing Equipment, Genomic Testing Services); Technology Type (Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology, Other Technology Types); Application (Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application, Other Applications); End-Use (Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 44 Featured) -

  • 23andMe
  • Ambry Genetics
  • BGI Genomics
  • Centogene N.V.
  • Color Health, Inc.
  • Exact Sciences Corporation
  • Foundation Medicine
  • Fulgent Genetics
  • GeneDx
  • Genomic Health (a subsidiary of Exact Sciences)
  • Guardant Health
  • Illumina, Inc.
  • Invitae Corporation
  • Luminex Corporation
  • Myriad Genetics
  • Natera, Inc.
  • NeoGenomics Laboratories
  • Oxford Nanopore Technologies
  • Qiagen
  • Thermo Fisher Scientific

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Precision Genomic Testing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Personalized Medicine Accelerates Adoption of Precision Genomic Testing
    • Increasing Awareness of Genetic Risk Factors for Disease Drives Growth in Precision Genomic Testing Applications
    • Surge in Preventive Healthcare and Early Disease Detection Expands Market Opportunity for Genomic Testing Solutions
    • Technological Advancements in CRISPR and Gene Editing Propel the Growth of Precision Genomic Testing
    • Growth in Direct-to-Consumer Genetic Testing Services Generates New Market Opportunities for Genomic Testing Providers
    • Rising Prevalence of Chronic Diseases and Cancer Accelerates Demand for Genomic Testing in Disease Prevention
    • Expansion of Genomic Research and Advancements in Bioinformatics Drives Innovation in Precision Genomic Testing
    • Increased Investment in Genomic Data Integration Technologies Strengthens the Case for Genomic Testing in Healthcare
    • Growing Focus on Pharmacogenomics and Tailored Drug Therapies Expands Market Demand for Genomic Testing Solutions
    • Rising Healthcare Expenditure Globally Accelerates Adoption of Precision Genomic Testing in Clinical Practice
    • Growing Popularity of Genetic Testing for Ancestry and Health Traits Drives Market Expansion
    • Integration of Artificial Intelligence and Machine Learning in Genomic Data Analysis Strengthens Adoption of Precision Genomic Testing
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Precision Genomic Testing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Precision Genomic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Precision Genomic Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Genomic Testing Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Genomic Testing Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Genomic Testing Equipment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Genomic Testing Equipment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Genomic Testing Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Genomic Testing Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Cardiovascular Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Cardiovascular Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Neurological Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Neurological Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Reproductive Health Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Reproductive Health Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Rare Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Rare Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Diagnostic Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Research & Academic Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Research & Academic Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 30: World Recent Past, Current & Future Analysis for Next-Generation Sequencing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 31: World 6-Year Perspective for Next-Generation Sequencing Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Polymerase Chain Reaction Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World 6-Year Perspective for Polymerase Chain Reaction Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Microarray Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 35: World 6-Year Perspective for Microarray Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 36: World Recent Past, Current & Future Analysis for Sanger Sequencing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 37: World 6-Year Perspective for Sanger Sequencing Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for CRISPR / CAS Systems Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World 6-Year Perspective for CRISPR / CAS Systems Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 40: World Recent Past, Current & Future Analysis for Other Technology Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 41: World 6-Year Perspective for Other Technology Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Precision Genomic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 42: USA Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: USA 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 46: USA Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: USA 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 48: USA Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: USA 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 52: Canada Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Canada 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 54: Canada Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Canada 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • JAPAN
    • Precision Genomic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 58: Japan Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Japan 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 60: Japan Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Japan 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 64: Japan Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Japan 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • CHINA
    • Precision Genomic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 66: China Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: China 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 70: China Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: China 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 72: China Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: China 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • EUROPE
    • Precision Genomic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Precision Genomic Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe 6-Year Perspective for Precision Genomic Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 76: Europe Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Europe 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 78: Europe Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Europe 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 82: Europe Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Europe 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • FRANCE
    • Precision Genomic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 84: France Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: France 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 88: France Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: France 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 90: France Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: France 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • GERMANY
    • Precision Genomic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 94: Germany Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Germany 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 96: Germany Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Germany 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • ITALY
    • TABLE 100: Italy Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Italy 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 102: Italy Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Italy 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 106: Italy Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Italy 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • UNITED KINGDOM
    • Precision Genomic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 108: UK Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 109: UK 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 112: UK Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 113: UK 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 114: UK Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 115: UK 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of Europe 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 118: Rest of Europe Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Rest of Europe 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 120: Rest of Europe Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Rest of Europe 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Europe 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Precision Genomic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 124: Asia-Pacific Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Asia-Pacific 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 126: Asia-Pacific Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 127: Asia-Pacific 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 130: Asia-Pacific Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 131: Asia-Pacific 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 132: Rest of World Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 133: Rest of World 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of World 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 136: Rest of World Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 137: Rest of World 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 138: Rest of World Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 139: Rest of World 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030

IV. COMPETITION